Answers are grounded in this paper and cite their sources.
Survey reveals current antenatal screening and treatment practices for congenital cytomegalovirus in Europe, highlighting potential for valaciclovir use.
Objective Congenital cytomegalovirus (cCMV) is the most common congenital infection globally, affecting approximately 0.5% of all live births in high income settings, with long-term sequelae affecting around a fifth of infected infants. Recently, interest in antenatal CMV screening has increased but current practices and impact are unclear. Our objective was to describe policy and practice around antenatal CMV screening, testing, and treatment in Europe, including the use of universal antenatal screening, in the context of the emerging evidence base for use of valaciclovir to reduce CMV vertical transmission (VT).
No takes yet. Share an insight, caveat, or question.
Ara et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: